Featured
| Oct 23 | Key Trends in the Pharmaceutical Pipeline for 2024 — Part I: Transformative R&D Growth Driven by Breakthroughs in Oncology, Neurological, and Metabolic Therapies read more » |
| Oct 22 | Sangamo to seek accelerated approval for Fabry gene therapy read more » |
| Oct 22 | Novel gene discovery paves the way for treating central nervous system injuries read more » |
| Oct 24 | CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study read more » |
| Oct 23 | More state Medicaid programs may soon cover Wegovy, Zepbound read more » |
| Oct 22 | Affinia Therapeutics to Highlight New Data on Genetic Cardiomyopathy Programs and BBB-Penetrant Capsids Leveraging Novel Receptors at the European Society of Gene & Cell Therapy 2024 31st Annual Congress read more » |
| Oct 22 | Orna Therapeutics Unveils Novel In Vivo Gene Editing Data Highlighting Engineering and Delivery Approach at the 31st Annual European Society of Gene & Cell Therapy Congress read more » |
| Oct 21 | Nanoscope Publishes Breakthrough Showing MCO-010 Treatment Arrests Neurodegeneration read more » |
| Oct 21 | Improving Gene Therapy Design and Manufacturability Using Synthetic Biology and AI read more » |
| Oct 23 | Single-cell chemoproteomics identifies metastatic activity signatures in breast cancer read more » |
| Oct 23 | Structuring lipid nanoparticles, DNA, and protein corona into stealth bionanoarchitectures for in vivo gene delivery read more » |
| Oct 23 | Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome read more » |
| Oct 23 | The role of polymers in enabling RNAi-based technology for sustainable pest management | Nature Communications read more » |
| Oct 23 | Disease background influences fate of transplanted stem cells read more » |
| Oct 23 | AI-designed DNA sequences regulate cell-type-specific gene expression read more » |
| Oct 23 | Long-term lineage commitment in hematopoietic stem cell gene therapy read more » |
| Oct 17 | CRISPRi-mediated metabolic switch enables concurrent aerobic and synthetic anaerobic fermentations in engineered consortium read more » |
| Oct 08 | Efficient and Safe In Vivo Treatment of Primary Hyperoxaluria Type 1 via LNP-CRISPR/Cas9-mediated glycolate oxidase disruption read more » |
PackGene’s Newsletter
Receive the latest news and insights to your inbox.
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Preclinical Studies Highlight Novel Gene Therapy for IgA Nephropathy Treatment
San Diego, CA – October 28, 2024 At the recent ASN Kidney Week 2024 (October 23–27), researchers presented promising preclinical data on PS-002, an innovative gene therapy aimed at treating IgA nephropathy (IgAN), an autoimmune kidney disease. The therapy, developed...
Lipin1 Inhibition Enhances Axon Regeneration: A Potential Therapeutic Approach for Spinal Cord Injury
Traumatic injuries to the central nervous system (CNS) often result in permanent functional deficits due to the limited capacity of CNS neurons to regenerate. Although advancements in spinal cord injury (SCI) research have been made, achieving substantial nerve fiber...
CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study
The promise of a one-and-done CRISPR infusion is beginning to look more real than ever. On Thursday, Intellia Therapeutics announced that an experimental gene editing therapy reduced dangerous and unpredictable swelling attacks caused by the disease hereditary...
Sangamo Therapeutics Secures Accelerated Approval Pathway for Gene Therapy in Fabry Disease
Sangamo Therapeutics has announced a major advancement in its gene therapy program for Fabry disease, as the U.S. FDA has provided a clear pathway for Accelerated Approval. This decision could potentially speed up approval timelines by three years, with a Biologics...
Related Services
AAV Packaging Services
READ MORE
Off-the-Shelf AAV Products
READ MORE
